Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Immuron Ltd/ 6-K

SEC Filing · 6-K

Immuron Ltd

SEC Filing

Filed Jul 21, 2026Accepted Jul 20, 2026, 9:37 PM EDTCIK 1660046Accession 0001213900-26-079777
View company →Permanent SEC source ↗
Share

Company context

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

Current securities

IMRNNASDAQ · ADR · Current
Historical securities (1)
IMRNWNASDAQ · WARRANT · Historical · closed Jun 13, 2022

Recent company filings

  1. 20-F filingSep 24, 2026
  2. 6-K filingSep 24, 2026
  3. 6-K filingSep 22, 2026
  4. 6-K filingSep 4, 2026
  5. 6-K filingAug 28, 2026

As-filed source

Primary evidence
As filedOpen full document ↗